Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs TransMedics Group Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $36.72 (market cap $2.98B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN and TransMedics Group Inc are close in size by market cap, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MicroSectors FANG and Innovation 3X Leveraged ETN for 19 Days and TransMedics Group Inc for 24 Days on average.
| FNGU | TMDX | |
|---|---|---|
Market Cap | $2.98B | $2.74B |
Volume | 4,682,352 | 949,331 |
Sector | Leveraged / Inverse | Health |
52-Week High | $37.20 | $150.42 |
52-Week Low | $13.73 | $61.99 |
Typical Hold Time | 19 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU, a 3x leveraged ETN tracking major tech stocks, trades at $36.82, down 1.02% today. Technical signals are bullish based on moving averages, with neutral oscillators suggesting potential consolidation. Support and resistance levels are tightly clustered between $33 and $39, indicating a critical price zone. Recent news highlights the ETN's high volatility, having lost 87% during past tech sector downturns, underscoring its leveraged risk profile.
The outlook for FNGU hinges on sustained strength in its underlying tech holdings like Nvidia and Apple. While bullish momentum offers upside potential, the extreme leverage amplifies risks during market corrections. Investors face significant volatility, with losses magnified in downturns, making it suitable only for those with high risk tolerance and short-term horizons.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
